| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 84 | 2024 | 10900 | 7.130 |
Why?
|
| Stroke Volume | 46 | 2024 | 5007 | 5.000 |
Why?
|
| Galectin 3 | 10 | 2019 | 227 | 3.000 |
Why?
|
| Exercise Tolerance | 14 | 2023 | 770 | 2.590 |
Why?
|
| Hypertension, Pulmonary | 9 | 2023 | 1537 | 2.320 |
Why?
|
| Cardiovascular Diseases | 36 | 2023 | 15165 | 2.180 |
Why?
|
| Ventricular Function, Left | 22 | 2023 | 3670 | 2.130 |
Why?
|
| Exercise Test | 17 | 2024 | 2074 | 2.040 |
Why?
|
| Obesity | 19 | 2023 | 12745 | 1.590 |
Why?
|
| Atrial Fibrillation | 11 | 2024 | 5034 | 1.580 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2023 | 581 | 1.530 |
Why?
|
| Growth Differentiation Factor 15 | 6 | 2014 | 176 | 1.500 |
Why?
|
| Pulmonary Wedge Pressure | 5 | 2023 | 264 | 1.290 |
Why?
|
| Receptors, Cell Surface | 8 | 2015 | 2866 | 1.190 |
Why?
|
| Insulin Resistance | 9 | 2023 | 3864 | 1.050 |
Why?
|
| Dyspnea | 7 | 2023 | 1303 | 0.960 |
Why?
|
| Atherosclerosis | 6 | 2023 | 3445 | 0.940 |
Why?
|
| Middle Aged | 97 | 2024 | 213383 | 0.910 |
Why?
|
| Blood Proteins | 7 | 2022 | 1124 | 0.900 |
Why?
|
| Hemodynamics | 8 | 2023 | 4199 | 0.890 |
Why?
|
| Metabolome | 8 | 2020 | 895 | 0.880 |
Why?
|
| Risk Factors | 59 | 2023 | 72290 | 0.860 |
Why?
|
| Inflammation Mediators | 2 | 2022 | 1889 | 0.850 |
Why?
|
| Heart Ventricles | 6 | 2022 | 3821 | 0.830 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2018 | 2073 | 0.800 |
Why?
|
| Proteomics | 7 | 2023 | 3638 | 0.800 |
Why?
|
| Humans | 170 | 2024 | 744343 | 0.790 |
Why?
|
| Ventricular Function, Right | 4 | 2023 | 591 | 0.760 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2021 | 859 | 0.750 |
Why?
|
| Pulmonary Artery | 4 | 2023 | 1912 | 0.740 |
Why?
|
| Female | 111 | 2024 | 380194 | 0.740 |
Why?
|
| Hypertension | 6 | 2023 | 8480 | 0.740 |
Why?
|
| C-Reactive Protein | 8 | 2023 | 3778 | 0.730 |
Why?
|
| Incidence | 25 | 2023 | 20947 | 0.730 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 231 | 0.720 |
Why?
|
| Male | 103 | 2024 | 350118 | 0.720 |
Why?
|
| Prognosis | 26 | 2024 | 29063 | 0.720 |
Why?
|
| Heart Rate | 4 | 2020 | 4091 | 0.710 |
Why?
|
| Sex Factors | 11 | 2021 | 10397 | 0.710 |
Why?
|
| Respiratory Function Tests | 2 | 2021 | 1616 | 0.680 |
Why?
|
| Systole | 5 | 2020 | 958 | 0.670 |
Why?
|
| Myocardium | 6 | 2020 | 4776 | 0.660 |
Why?
|
| Phenotype | 6 | 2023 | 16365 | 0.660 |
Why?
|
| Infertility | 2 | 2023 | 655 | 0.650 |
Why?
|
| Adipokines | 2 | 2020 | 319 | 0.650 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.650 |
Why?
|
| Oxygen Consumption | 4 | 2024 | 1869 | 0.640 |
Why?
|
| Dyslipidemias | 2 | 2016 | 849 | 0.640 |
Why?
|
| Aged | 62 | 2023 | 163280 | 0.640 |
Why?
|
| Troponin | 3 | 2023 | 524 | 0.620 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2021 | 849 | 0.590 |
Why?
|
| Calcium-Binding Proteins | 1 | 2021 | 1081 | 0.570 |
Why?
|
| Sex Characteristics | 3 | 2022 | 2585 | 0.570 |
Why?
|
| Body Mass Index | 13 | 2022 | 12720 | 0.550 |
Why?
|
| Inflammation | 6 | 2023 | 10638 | 0.550 |
Why?
|
| Hospitalization | 9 | 2023 | 10262 | 0.550 |
Why?
|
| Natriuretic Peptide, Brain | 8 | 2019 | 1573 | 0.540 |
Why?
|
| Albuminuria | 3 | 2017 | 682 | 0.540 |
Why?
|
| Heptanoic Acids | 3 | 2012 | 343 | 0.540 |
Why?
|
| Heart Diseases | 3 | 2023 | 2788 | 0.540 |
Why?
|
| Cardiovascular System | 2 | 2023 | 832 | 0.530 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2023 | 2208 | 0.510 |
Why?
|
| Troponin I | 3 | 2014 | 619 | 0.500 |
Why?
|
| Adult | 56 | 2024 | 214055 | 0.500 |
Why?
|
| Proportional Hazards Models | 13 | 2021 | 12354 | 0.500 |
Why?
|
| Cardiomyopathies | 5 | 2023 | 1912 | 0.500 |
Why?
|
| Longitudinal Studies | 14 | 2023 | 13989 | 0.490 |
Why?
|
| Electrocardiography | 5 | 2024 | 6442 | 0.480 |
Why?
|
| Brachial Artery | 3 | 2012 | 369 | 0.470 |
Why?
|
| Lung | 6 | 2022 | 9856 | 0.470 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2017 | 3255 | 0.470 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 101 | 0.460 |
Why?
|
| Coronary Disease | 6 | 2014 | 6077 | 0.460 |
Why?
|
| Carbolines | 1 | 2014 | 265 | 0.430 |
Why?
|
| Stroke | 7 | 2023 | 9981 | 0.430 |
Why?
|
| Diabetes Mellitus | 6 | 2023 | 5751 | 0.430 |
Why?
|
| Obesity, Abdominal | 1 | 2015 | 361 | 0.430 |
Why?
|
| Prospective Studies | 23 | 2023 | 53288 | 0.430 |
Why?
|
| Myocardial Infarction | 8 | 2023 | 11727 | 0.430 |
Why?
|
| Resistin | 2 | 2023 | 170 | 0.430 |
Why?
|
| Pulmonary Fibrosis | 1 | 2016 | 530 | 0.410 |
Why?
|
| Cardiology | 1 | 2023 | 1668 | 0.410 |
Why?
|
| Coronary Artery Disease | 8 | 2022 | 6487 | 0.410 |
Why?
|
| Eicosanoids | 2 | 2023 | 279 | 0.410 |
Why?
|
| Massachusetts | 9 | 2021 | 8663 | 0.400 |
Why?
|
| Follow-Up Studies | 23 | 2021 | 39050 | 0.400 |
Why?
|
| Metabolomics | 2 | 2020 | 1484 | 0.400 |
Why?
|
| Adiponectin | 3 | 2023 | 1100 | 0.390 |
Why?
|
| Pyrroles | 3 | 2012 | 1146 | 0.390 |
Why?
|
| Risk Assessment | 12 | 2023 | 23338 | 0.390 |
Why?
|
| Menopause, Premature | 2 | 2023 | 132 | 0.380 |
Why?
|
| Exercise | 7 | 2022 | 5615 | 0.380 |
Why?
|
| Triglycerides | 5 | 2019 | 2454 | 0.370 |
Why?
|
| Heart Conduction System | 1 | 2016 | 1047 | 0.370 |
Why?
|
| American Heart Association | 6 | 2023 | 1056 | 0.360 |
Why?
|
| Diastole | 5 | 2015 | 791 | 0.350 |
Why?
|
| Predictive Value of Tests | 12 | 2023 | 15076 | 0.350 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 15540 | 0.340 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 332 | 0.340 |
Why?
|
| Leptin | 3 | 2023 | 1599 | 0.340 |
Why?
|
| Interleukins | 1 | 2013 | 791 | 0.330 |
Why?
|
| Echocardiography | 8 | 2021 | 5102 | 0.320 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2012 | 4386 | 0.320 |
Why?
|
| Blood Glucose | 5 | 2018 | 6256 | 0.320 |
Why?
|
| Forecasting | 2 | 2017 | 2951 | 0.320 |
Why?
|
| Galectins | 4 | 2019 | 268 | 0.310 |
Why?
|
| HIV Infections | 9 | 2020 | 16718 | 0.310 |
Why?
|
| Cause of Death | 3 | 2018 | 3584 | 0.300 |
Why?
|
| Interleukin-6 | 3 | 2023 | 3200 | 0.300 |
Why?
|
| Prediabetic State | 1 | 2013 | 499 | 0.300 |
Why?
|
| Women's Health | 2 | 2022 | 2034 | 0.300 |
Why?
|
| Heart | 6 | 2022 | 4467 | 0.290 |
Why?
|
| Blood Pressure | 7 | 2022 | 8554 | 0.290 |
Why?
|
| Mortality | 4 | 2021 | 2864 | 0.290 |
Why?
|
| Ventricular Remodeling | 3 | 2023 | 1224 | 0.290 |
Why?
|
| Electronic Health Records | 1 | 2023 | 4468 | 0.270 |
Why?
|
| Echocardiography, Doppler | 3 | 2016 | 935 | 0.270 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 1956 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2018 | 15519 | 0.270 |
Why?
|
| Benzazepines | 1 | 2008 | 326 | 0.270 |
Why?
|
| United States | 19 | 2023 | 69872 | 0.270 |
Why?
|
| Cohort Studies | 14 | 2021 | 40561 | 0.260 |
Why?
|
| Cholesterol, HDL | 3 | 2018 | 1814 | 0.260 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 2170 | 0.260 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2015 | 72 | 0.250 |
Why?
|
| Fibrosis | 3 | 2020 | 2029 | 0.250 |
Why?
|
| Peptide Fragments | 4 | 2019 | 5097 | 0.250 |
Why?
|
| Prevalence | 7 | 2023 | 15226 | 0.240 |
Why?
|
| Odds Ratio | 6 | 2020 | 9849 | 0.240 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2021 | 783 | 0.240 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1797 | 0.240 |
Why?
|
| Linear Models | 4 | 2020 | 5952 | 0.230 |
Why?
|
| Insulin | 4 | 2019 | 6580 | 0.230 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 7913 | 0.220 |
Why?
|
| Epoxy Compounds | 1 | 2023 | 136 | 0.220 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 25043 | 0.220 |
Why?
|
| Logistic Models | 4 | 2021 | 13408 | 0.220 |
Why?
|
| Genome-Wide Association Study | 11 | 2023 | 12261 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6538 | 0.220 |
Why?
|
| Simvastatin | 2 | 2017 | 360 | 0.220 |
Why?
|
| Linoleic Acid | 1 | 2023 | 157 | 0.210 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 6773 | 0.210 |
Why?
|
| Growth Differentiation Factors | 1 | 2022 | 98 | 0.210 |
Why?
|
| Cluster Analysis | 2 | 2023 | 2715 | 0.200 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 12245 | 0.200 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2023 | 1265 | 0.200 |
Why?
|
| Genome, Human | 2 | 2013 | 4420 | 0.200 |
Why?
|
| Insulin-Secreting Cells | 3 | 2019 | 891 | 0.190 |
Why?
|
| Signal Transduction | 3 | 2021 | 23403 | 0.190 |
Why?
|
| Tunica Media | 2 | 2011 | 113 | 0.190 |
Why?
|
| Quantitative Trait Loci | 3 | 2021 | 2019 | 0.180 |
Why?
|
| Complement Factor D | 1 | 2019 | 68 | 0.180 |
Why?
|
| Algorithms | 1 | 2020 | 13881 | 0.180 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 57776 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2019 | 47 | 0.180 |
Why?
|
| Complement C3a | 1 | 2019 | 69 | 0.180 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2019 | 73 | 0.180 |
Why?
|
| Teaching Rounds | 1 | 2023 | 253 | 0.170 |
Why?
|
| Terrorism | 1 | 2002 | 211 | 0.170 |
Why?
|
| Peroxidase | 1 | 2022 | 611 | 0.170 |
Why?
|
| Live Birth | 1 | 2023 | 512 | 0.170 |
Why?
|
| Aneurysm | 1 | 2022 | 339 | 0.170 |
Why?
|
| Mass Screening | 1 | 2015 | 5255 | 0.170 |
Why?
|
| Adiposity | 2 | 2021 | 1807 | 0.170 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2020 | 314 | 0.160 |
Why?
|
| Asymptomatic Diseases | 2 | 2018 | 551 | 0.160 |
Why?
|
| Pulmonary Ventilation | 1 | 2020 | 373 | 0.160 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2020 | 382 | 0.160 |
Why?
|
| Time Factors | 9 | 2020 | 40075 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2012 | 1873 | 0.150 |
Why?
|
| Oxygen | 3 | 2023 | 4189 | 0.150 |
Why?
|
| Retrospective Studies | 9 | 2023 | 77449 | 0.150 |
Why?
|
| Life Change Events | 1 | 2002 | 938 | 0.150 |
Why?
|
| Kidney | 6 | 2023 | 7186 | 0.150 |
Why?
|
| Spironolactone | 1 | 2020 | 382 | 0.150 |
Why?
|
| Pulmonary Circulation | 1 | 2020 | 739 | 0.150 |
Why?
|
| Education | 1 | 2020 | 543 | 0.150 |
Why?
|
| Research Report | 1 | 2020 | 355 | 0.150 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2021 | 712 | 0.140 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 2214 | 0.140 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 745 | 0.140 |
Why?
|
| Amyloidosis | 1 | 2023 | 795 | 0.140 |
Why?
|
| Patient Readmission | 2 | 2023 | 3114 | 0.140 |
Why?
|
| Disasters | 1 | 2002 | 511 | 0.140 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 851 | 0.130 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2022 | 686 | 0.130 |
Why?
|
| Age Factors | 5 | 2021 | 18370 | 0.130 |
Why?
|
| Myocarditis | 1 | 2023 | 771 | 0.130 |
Why?
|
| Pravastatin | 1 | 2017 | 395 | 0.130 |
Why?
|
| Isocitrates | 1 | 2015 | 24 | 0.130 |
Why?
|
| Hormones | 1 | 2019 | 889 | 0.130 |
Why?
|
| Cardiac Output | 1 | 2018 | 854 | 0.130 |
Why?
|
| Taurocholic Acid | 1 | 2015 | 43 | 0.130 |
Why?
|
| Aldosterone | 1 | 2020 | 877 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2021 | 1082 | 0.130 |
Why?
|
| Singapore | 1 | 2016 | 295 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2012 | 2559 | 0.130 |
Why?
|
| Natural Language Processing | 1 | 2023 | 1041 | 0.130 |
Why?
|
| Waist Circumference | 2 | 2015 | 917 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2019 | 11725 | 0.120 |
Why?
|
| Independent Living | 1 | 2018 | 568 | 0.120 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 19905 | 0.120 |
Why?
|
| Viral Load | 3 | 2012 | 3299 | 0.120 |
Why?
|
| 2-Aminoadipic Acid | 1 | 2013 | 33 | 0.120 |
Why?
|
| Gene Deletion | 1 | 2021 | 2751 | 0.120 |
Why?
|
| Survival Rate | 4 | 2017 | 12788 | 0.120 |
Why?
|
| Cholesterol | 2 | 2018 | 2917 | 0.120 |
Why?
|
| Plasma | 1 | 2016 | 575 | 0.110 |
Why?
|
| HIV | 1 | 2020 | 1604 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 1240 | 0.110 |
Why?
|
| Cell-Derived Microparticles | 1 | 2014 | 168 | 0.110 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 1354 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 658 | 0.110 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 464 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 2 | 2020 | 1715 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1199 | 0.100 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 317 | 0.100 |
Why?
|
| Neoplasms | 4 | 2023 | 21683 | 0.100 |
Why?
|
| Calcinosis | 2 | 2011 | 1499 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1194 | 0.100 |
Why?
|
| Health Status | 1 | 2005 | 4034 | 0.100 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 684 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 1031 | 0.100 |
Why?
|
| Endothelium, Vascular | 3 | 2014 | 4456 | 0.100 |
Why?
|
| Life Style | 1 | 2002 | 3835 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2022 | 5317 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3870 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2020 | 63114 | 0.090 |
Why?
|
| Health Behavior | 1 | 2022 | 2636 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2022 | 3279 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2019 | 2240 | 0.090 |
Why?
|
| Aortic Valve Stenosis | 1 | 2022 | 1965 | 0.090 |
Why?
|
| Glucose Tolerance Test | 1 | 2013 | 1150 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2016 | 4217 | 0.090 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2012 | 272 | 0.090 |
Why?
|
| Fasting | 1 | 2016 | 1593 | 0.090 |
Why?
|
| Netherlands | 3 | 2020 | 2170 | 0.090 |
Why?
|
| Endothelium | 1 | 2012 | 778 | 0.090 |
Why?
|
| Case-Control Studies | 6 | 2019 | 21746 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2023 | 8324 | 0.090 |
Why?
|
| Dideoxynucleosides | 1 | 2009 | 122 | 0.090 |
Why?
|
| Morbidity | 1 | 2015 | 1769 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2014 | 12026 | 0.080 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2013 | 571 | 0.080 |
Why?
|
| Registries | 2 | 2023 | 8089 | 0.080 |
Why?
|
| Nifedipine | 1 | 2009 | 226 | 0.080 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 1791 | 0.080 |
Why?
|
| Action Potentials | 1 | 2016 | 1806 | 0.080 |
Why?
|
| Vasodilation | 2 | 2009 | 944 | 0.080 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2009 | 138 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2023 | 17446 | 0.080 |
Why?
|
| Hospitals | 1 | 2022 | 3952 | 0.080 |
Why?
|
| Data Mining | 1 | 2013 | 537 | 0.080 |
Why?
|
| Potassium | 1 | 2012 | 1336 | 0.080 |
Why?
|
| Heart Atria | 1 | 2014 | 1357 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2023 | 3752 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2018 | 2616 | 0.070 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 688 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 35421 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2002 | 4245 | 0.070 |
Why?
|
| Longevity | 1 | 2015 | 1070 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2011 | 952 | 0.070 |
Why?
|
| Biological Specimen Banks | 2 | 2023 | 711 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2009 | 464 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2019 | 2987 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 8949 | 0.070 |
Why?
|
| Blood Volume | 1 | 2008 | 565 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2018 | 2297 | 0.070 |
Why?
|
| RNA, Viral | 2 | 2012 | 2902 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 3846 | 0.070 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2009 | 615 | 0.070 |
Why?
|
| Lipids | 1 | 2017 | 3305 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2019 | 3110 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2009 | 690 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 892 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 21827 | 0.070 |
Why?
|
| Heart Defects, Congenital | 1 | 2022 | 4584 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2008 | 629 | 0.070 |
Why?
|
| Rest | 1 | 2010 | 901 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2022 | 925 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2013 | 2499 | 0.060 |
Why?
|
| Patient Transfer | 1 | 2011 | 761 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 604 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2020 | 3309 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2009 | 789 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 841 | 0.060 |
Why?
|
| HEK293 Cells | 1 | 2013 | 4204 | 0.060 |
Why?
|
| Ultrasonography | 3 | 2012 | 5985 | 0.060 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2011 | 1873 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2703 | 0.060 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2023 | 964 | 0.060 |
Why?
|
| Adrenomedullin | 1 | 2023 | 87 | 0.060 |
Why?
|
| Diet | 1 | 2021 | 7939 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2013 | 5456 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 10943 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2009 | 882 | 0.050 |
Why?
|
| Motor Activity | 1 | 2013 | 2714 | 0.050 |
Why?
|
| Forced Expiratory Volume | 2 | 2022 | 1743 | 0.050 |
Why?
|
| Acute Disease | 2 | 2015 | 7149 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 1 | 2009 | 1504 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2008 | 1572 | 0.050 |
Why?
|
| Disease Progression | 3 | 2014 | 13284 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 2268 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 5867 | 0.050 |
Why?
|
| Boston | 1 | 2014 | 9313 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2011 | 9959 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 2148 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 3760 | 0.050 |
Why?
|
| Aging | 1 | 2020 | 8664 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 29144 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 1889 | 0.050 |
Why?
|
| Physical Exertion | 1 | 2023 | 695 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 13695 | 0.050 |
Why?
|
| Gene Expression | 1 | 2013 | 7799 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 676 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 4933 | 0.040 |
Why?
|
| New York | 1 | 2002 | 886 | 0.040 |
Why?
|
| Follistatin-Related Proteins | 1 | 2019 | 48 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2005 | 2971 | 0.040 |
Why?
|
| Spirometry | 1 | 2022 | 864 | 0.040 |
Why?
|
| Mice | 3 | 2021 | 81183 | 0.040 |
Why?
|
| Comorbidity | 2 | 2023 | 10388 | 0.040 |
Why?
|
| Natriuretic Peptides | 1 | 2020 | 150 | 0.040 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 135 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 1107 | 0.040 |
Why?
|
| Death | 1 | 2023 | 678 | 0.040 |
Why?
|
| Population Growth | 1 | 2018 | 52 | 0.040 |
Why?
|
| Calcium | 1 | 2011 | 5756 | 0.040 |
Why?
|
| Young Adult | 4 | 2019 | 56430 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 290 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 342 | 0.040 |
Why?
|
| Aortic Aneurysm | 1 | 2021 | 643 | 0.040 |
Why?
|
| Endothelial Cells | 2 | 2023 | 3479 | 0.040 |
Why?
|
| Xanthines | 1 | 2016 | 121 | 0.030 |
Why?
|
| Ribonucleosides | 1 | 2016 | 82 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2021 | 689 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2020 | 695 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2002 | 2373 | 0.030 |
Why?
|
| Animals | 4 | 2021 | 168757 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2002 | 1203 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 2007 | 0.030 |
Why?
|
| Educational Status | 1 | 2003 | 2540 | 0.030 |
Why?
|
| Liver | 1 | 2011 | 7474 | 0.030 |
Why?
|
| Menopause | 1 | 2023 | 1626 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 12072 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2019 | 692 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 1878 | 0.030 |
Why?
|
| Diet, Mediterranean | 1 | 2021 | 700 | 0.030 |
Why?
|
| Aorta | 1 | 2022 | 2061 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2019 | 850 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2019 | 1959 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 4256 | 0.030 |
Why?
|
| Cholesterol Esters | 1 | 2013 | 73 | 0.030 |
Why?
|
| Postmenopause | 1 | 2002 | 2461 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 20129 | 0.030 |
Why?
|
| Smoking | 2 | 2014 | 8987 | 0.030 |
Why?
|
| Transaminases | 1 | 2013 | 199 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2015 | 5078 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2013 | 290 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 7279 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2309 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2019 | 1379 | 0.030 |
Why?
|
| Mutation | 1 | 2016 | 29786 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 976 | 0.020 |
Why?
|
| Wound Healing | 1 | 2022 | 2785 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2019 | 1373 | 0.020 |
Why?
|
| Adolescent | 2 | 2018 | 85781 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 5391 | 0.020 |
Why?
|
| Risk | 2 | 2013 | 9687 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 4740 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 2635 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2019 | 1938 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3508 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2016 | 3588 | 0.020 |
Why?
|
| Research Design | 1 | 2005 | 5987 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 3966 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2013 | 2008 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 676 | 0.020 |
Why?
|
| HIV-1 | 2 | 2019 | 6939 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 2203 | 0.020 |
Why?
|
| Glucose | 1 | 2019 | 4397 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2021 | 9146 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 1919 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 4982 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2011 | 1534 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2009 | 977 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 1590 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2020 | 10481 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2023 | 25625 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2014 | 4026 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2013 | 6459 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 2046 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2012 | 1470 | 0.010 |
Why?
|
| Homeostasis | 1 | 2013 | 3340 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 9438 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2015 | 10252 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2011 | 3107 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2011 | 3086 | 0.010 |
Why?
|
| Equipment Design | 1 | 2008 | 3582 | 0.010 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 1177 | 0.010 |
Why?
|
| Cell Line | 1 | 2013 | 15997 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2008 | 5788 | 0.000 |
Why?
|